ArticleCell death & disease2026
14-3-3γ Knockdown promotes matrix mineralization in human mesenchymal stromal cells.
Article in Cell death & disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The 14-3-3 proteins are emerging as important modulators of osteoblast differentiation and function. Recent studies highlight specific roles of 14-3-3 paralogs in bone physiology, with their dysregulation linked to impaired skeletal homeostasis and bone-related diseases. Among these, the 14-3-3γ paralog has been implicated in bone formation, though its precise role remains unclear.In this study, we investigated the function of 14-3-3γ in the osteogenic differentiation of human adipose-derived mesenchymal stem/stromal cells (hASCs). Using an adenoviral system, we knocked down 14-3-3γ and assessed osteogenic markers. Tissue-Nonspecific Alkaline Phosphatase (TNAP) activity, RUNX2 protein levels, and the expression of osteogenic genes (BGLAP, SPP1) were analyzed during matrix maturation and mineralization. Calcium and collagen deposition were evaluated via Alizarin Red S and Aniline Blue staining, respectively, and compared with cells overexpressing recombinant 14-3-3γ. Proteomic profiling via quantitative mass spectrometry was performed to identify protein changes after 14-3-3γ silencing. Subcellular localization of endogenous 14-3-3γ was also examined during differentiation. Knockdown of 14-3-3γ enhanced TNAP activity and increased matrix mineralization, while its overexpression suppressed these processes. Proteomic analysis revealed enrichment of proteins related to endoplasmic reticulum stress and bone development. Furthermore, 14-3-3γ shifted from a diffuse to a peri-endoplasmic reticulum distribution, with increased colocalization with calnexin during osteogenic induction. These findings reveal a novel inhibitory role of 14-3-3γ in matrix mineralization of hASCs, suggesting that targeting this paralog may offer new avenues for therapies in bone remodeling disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.